YUMAB
LIVE

Serial Number

79191669

Owner

YUMAB GmbH

Attorney

Joseph V. Norvell

Filing Date

Apr 25, 2016

Add to watchlist:

No watchlists yet
View on USPTO

YUMAB Trademark

Serial Number: 79191669 • Registration: 5238680

YUMAB is a trademark filed by YUMAB GmbH on April 25, 2016. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

YUMAB GmbH

Science Campus Braunschweig-Süd,
Braunschweig 38124 , DE

Entity Type: 27

Trademark Details

Filing Date

April 25, 2016

Registration Date

July 11, 2017

Published for Opposition

April 25, 2017

Goods & Services

Scientific research; technological services being antibody engineering and design; industrial analysis and research services in the nature of laboratory research and new product design services relating to the production of monoclonal antibodies

[ Monoclonal antibodies for quantitative determination of leukocyte subsets other than for medical purposes; chemicals components being biochemicals for producing radio-labelled monoclonal antibodies for industrial or scientific purposes; proteins for detecting antibodies other than for medical purposes; ] monoclonal antibodies for industrial use; monoclonal antibody reagents, other than for medical use; antigens and antibodies being biochemicals for diagnostic use not for medical purposes; immunological antibodies, being biochemicals, other than for medical use; tagged antibodies being biochemicals for scientific use; [ monoclonal antibodies for qualitative determination of leukocyte subsets other than for medical purposes; linkage compounds being biochemicals for scientific purposes for coupling of radioactive compounds to antibodies; reagents for use in the development of hybridoma antibodies other than for medical or veterinary purposes; ] biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; proteins for binding antibodies other than for medical purposes; monoclonal antibodies for scientific use; [ linkage compounds being biochemicals for scientific purposes for coupling antibodies to radio nuclides; monoclonal antibodies for research into haematopoietic systems other than for medical purposes; ] reagents for use in development of monoclonal antibodies other than for medical or veterinary purposes; [ components for producing radio-labelled antibody fragments for industrial or scientific purposes being biochemicals; ] tagged antibodies being biochemicals for laboratory use; reagents in kit form for conducting enzyme-linked immunosorbent assays (elisa) other than for medical or veterinary purposes comprised primarily of biochemicals

Antibodies, antibody fragments and antigens in the nature of pharmaceuticals for the treatment of cancer, haematopoietic diseases, autoimmune diseases, neurodegenerative diseases, metabolic diseases, eye diseases, infections, diseases of heart and circulation, bone diseases, transplantation, sepsis, intoxications, and adverse drug reactions

Filing History

INTERNATIONAL REGISTRATION RENEWED
Apr 30, 2026 RNWL
TOTAL INVALIDATION PROCESSED BY THE IB
Feb 8, 2025 INNT
GENERIC MADRID TRANSACTION SENT TO IB
Jan 15, 2025 XXSS
GENERIC MADRID TRANSACTION CREATED
Jan 15, 2025 XXCR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Dec 4, 2024 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Sep 27, 2024 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Sep 27, 2024 C75A
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Sep 17, 2024 EROP
POST REGISTRATION ACTION MAILED - SEC. 71 & 15
Apr 3, 2024 PR75
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 25, 2024 APRE
TEAS SECTION 71 & 15 RECEIVED
Jul 10, 2023 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Feb 18, 2023 NREP
CHANGE OF NAME/ADDRESS REC'D FROM IB
Aug 15, 2019 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 10, 2017 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 20, 2017 FICS
FINAL DISPOSITION PROCESSED
Oct 20, 2017 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 11, 2017 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 11, 2017 R.PR
PUBLISHED FOR OPPOSITION
Apr 25, 2017 PUBO
NOTIFICATION PROCESSED BY IB
Apr 22, 2017 GPNX
ASSIGNED TO EXAMINER
Apr 21, 2017 DOCK
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 5, 2017 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 5, 2017 OP2R
NOTICE OF PUBLICATION
Apr 5, 2017 NPUB
EXAMINERS AMENDMENT MAILED
Mar 20, 2017 CNEA
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 18, 2017 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 18, 2017 XAEC
EXAMINERS AMENDMENT -WRITTEN
Mar 18, 2017 CNEA
REFUSAL PROCESSED BY IB
Oct 16, 2016 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 28, 2016 RFCS
REFUSAL PROCESSED BY MPU
Sep 28, 2016 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 27, 2016 RFCR
NON-FINAL ACTION WRITTEN
Sep 26, 2016 CNRT
APPLICATION FILING RECEIPT MAILED
Sep 20, 2016 MAFR
ASSIGNED TO EXAMINER
Sep 16, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 16, 2016 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 15, 2016 REPR